medicina57巻3号

2020年03月発行

連載 物忘れ外来から学ぶ現場のコツ 認知症患者の診かた・22

認知症の周辺症状が急に悪化した場合には，どうしたらよいですか？

著者： 重松一生¹

所属機関： ¹南京都病院神経内科

ページ範囲：P.579 - P.583

ポイント
認知症の多くは潜行性発症，緩徐進行性です．ところが“急変”は決して稀でなく，かつその対応が極めて困難であることを忘れてはいけません．

参考文献

1）Ionis Pharmaceuticals: Safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS-MAPTRx in patients with mild Alzheimer's disease.　https://www.clinicaltrials.gov/ct2/show/NCT03186989

2）TauRx Therapeutics：Safety and efficacy of TRx0237 in subjects with Alzheimer's disease followed by open-label treatment.　https://clinicaltrials.gov/ct2/show/NCT03446001

3）Boxer A：A safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy study of TPI-287 in Alzheimer's disease.　https://clinicaltrials.gov/ct2/show/NCT01966666?term=TPI＋287＆cond=Alzheimer＋Disease＆draw=2＆rank=1

4）Turner RS：Impact of Nilotinib on safety, biomarkers and clinical outcomes in mild to moderate Alzheimer's disease（AD）.　https://www.clinicaltrials.gov/ct2/show/NCT02947893

5）Anavex Life Science：ANAVEX2-73 for treatment of early Alzheimer's disease.　https://clinicaltrials.gov/ct2/show/NCT03790709

6）エーザイ　ニュースリリース：脳脊髄液中のタウ微小管結合領域の定量化と新規抗タウ抗体E2814開発におけるターゲットエンゲージメントバイオマーカーの同定について．　https://www.eisai.co.jp/news/2019/news201955.html

7）Axon Neuroscience SE：18-months safety follow-up study of AADvac1, an active tau vaccine for Alzheimer's disease（FUNDAMANT）．　https://www.clinicaltrials.gov/ct2/show/NCT02031198

8）NIH National Institute of Aging：RO7105705 for prodromal to mild Alzheimer's disease,　https://www.nia.nih.gov/alzheimers/clinical-trials/ro7105705-prodromal-mild-alzheimers-disease

9）AbbVie：A study to evaluate the efficacy and safety of ABBV-8E12 in subjects with early Alzheimer's disease　https://www.clinicaltrials.gov/ct2/show/NCT02880956